$See \ discussions, stats, and \ author \ profiles \ for \ this \ publication \ at: \ https://www.researchgate.net/publication/383749495$

Supporting Lymphatic Function: Blood Transfusions in HIV and the Immune System

Article · September 2024

CITATIONS 0		READS	
2 authors:			
-	Emmanuel Ifeanyi Obeagu Africa University 2,100 PUBLICATIONS 36,090 CITATIONS SEE PROFILE		Getrude Uzoma Obeagu Kampala International University 649 PUBLICATIONS 18,724 CITATIONS SEE PROFILE

Supporting Lymphatic Function: Blood Transfusions in HIV and the Immune System

*Emmanuel Ifeanyi Obeagu¹ and Getrude Uzoma Obeagu²

¹Department of Medical Laboratory Science, Kampala International University, Uganda.

²School of Nursing Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Blood transfusions are integral to the management of HIV-positive individuals, particularly in addressing anemia and its broader implications on immune function. This review explores the role of blood transfusions in supporting lymphatic function and overall immune health in HIV patients. Transfusions alleviate anemia by enhancing oxygen delivery and reducing systemic inflammation, which in turn supports the health and function of lymphoid tissues and immune cells. The review highlights how these effects contribute to improved lymphatic function, better immune responses, and enhanced patient outcomes. HIV infection severely disrupts lymphatic function and lymphoid tissue integrity, impairing immune responses and increasing susceptibility to infections. Blood transfusions mitigate some of these effects by addressing anemia, thus improving oxygenation and reducing inflammatory stress on lymphoid tissues. This support helps maintain the functionality of lymphocytes and other immune cells, facilitating more effective immune surveillance and response.

Keywords: Blood Transfusions, HIV, Lymphatic Function, Immune System, Immune Cell Function

Introduction

Human Immunodeficiency Virus (HIV) profoundly affects the immune system, leading to severe complications such as immunodeficiency and increased susceptibility to opportunistic infections. One critical aspect of HIV-related complications is its impact on lymphatic function and lymphoid tissue integrity. The lymphatic system, comprising lymph nodes, spleen, and other lymphoid organs, plays a pivotal role in immune surveillance and response. HIV disrupts the normal architecture and function of these tissues, impairing the body's ability to mount effective immune **Citation**: Obeagu EI, Obeagu GU. Supporting Lymphatic Function: Blood Transfusions in HIV and the Immune System. Elite Journal of Medical Sciences, 2024; 2(9):12-20

responses and leading to compromised immune health.¹⁻² Anemia is a common complication in HIV-positive individuals, contributing to fatigue, reduced physical capacity, and overall deterioration in quality of life. The condition exacerbates the challenges faced by HIV patients by further weakening their already compromised immune systems. Blood transfusions are frequently employed to manage anemia, but their benefits extend beyond mere hematologic improvement. By addressing anemia, transfusions enhance oxygen delivery to tissues, including lymphoid organs, thus supporting their function and overall health.³⁻⁵ The role of blood transfusions in HIV care has been well-documented in terms of managing anemia, but their effects on lymphatic function and immune health are less explored. Transfusions help restore hemoglobin levels, thereby improving oxygenation and reducing systemic inflammation. These improvements can have a significant impact on lymphoid tissues, which are crucial for effective immune function. By supporting the health of these tissues, transfusions can enhance immune responses and help maintain the integrity of the lymphatic system.⁶⁻⁸

HIV-related damage to lymphoid tissues leads to disrupted immune responses and increased vulnerability to infections. This disruption affects the lymph nodes and spleen, reducing their ability to filter pathogens and present antigens. Blood transfusions can mitigate some of these effects by improving oxygenation and reducing inflammation, which in turn supports lymphoid tissue function. This review examines how blood transfusions contribute to the restoration of lymphatic function and the overall health of the immune system in HIV-positive individuals.⁹⁻¹⁰ Integrating transfusion therapy into a comprehensive care approach can enhance the effectiveness of antiretroviral therapy (ART) and other supportive treatments. This holistic approach aims to address both the hematologic and immunological aspects of HIV, leading to improved patient outcomes and quality of life.¹¹⁻¹²

Impact of HIV on Lymphatic Function

HIV infection profoundly disrupts lymphatic function and the integrity of lymphoid tissues, which are essential for maintaining a robust immune system. The virus primarily targets CD4+ T cells, crucial components of the immune system that are instrumental in coordinating immune responses. The depletion of these cells, coupled with chronic immune activation and inflammation, leads to significant alterations in lymphatic function and lymphoid tissue architecture.¹³⁻¹⁴ HIV infection leads to a progressive loss of lymphoid tissue, including lymph nodes and the spleen. The virus-induced destruction of CD4+ T cells results in the collapse of the organized structure of lymphoid tissues. In lymph nodes, this results in the loss of follicles, which are crucial for the initiation and regulation of immune responses. The disruption of these structures impairs the ability of lymph nodes to effectively filter pathogens and present antigens to T cells. Similarly, the spleen, which plays a role in filtering blood and mounting immune responses against blood-borne pathogens, experiences reduced functionality.¹⁵⁻¹⁶ The loss of CD4+ T cells and the subsequent decline in lymphoid tissue integrity directly impact immune cell function. CD4+ T cells are essential for the activation and coordination of other immune cells, including B cells and cytotoxic T cells. As their numbers decline, the ability to mount effective immune responses is severely compromised. This

Elite Journal of Medical Sciences. Volume 2 issue 9 (2024), Pp.12-20

https://epjournals.com/journals/EJMS

impairment affects the production of antibodies, the activation of cytotoxic T cells, and the overall efficiency of immune surveillance and pathogen clearance.¹⁷⁻¹⁸

HIV infection is characterized by chronic immune activation and systemic inflammation. The ongoing destruction of lymphoid tissue and the continuous presence of the virus lead to a state of persistent inflammation. This inflammation further exacerbates lymphoid tissue damage, creating a vicious cycle that impairs immune function. Chronic inflammation also contributes to the development of comorbid conditions, such as cardiovascular disease and metabolic disorders, which further complicate the management of HIV.¹⁹⁻²⁰ The integrity of the lymphatic system is essential for maintaining fluid balance, filtering pathogens, and supporting immune responses. HIV-induced damage to lymphoid tissues disrupts these functions, leading to compromised lymphatic drainage and an increased risk of opportunistic infections. The impaired ability to filter lymph and blood can result in the accumulation of pathogens and cellular debris, further compromising immune function and increasing susceptibility to infections.²¹⁻²² The impact of HIV on lymphatic function underscores the importance of addressing both the hematologic and immunological aspects of the disease in management strategies. Understanding how HIV affects lymphoid tissues helps in designing targeted interventions, including the use of blood transfusions and other supportive therapies. By addressing the damage to lymphatic function and supporting immune health, healthcare providers can improve the overall management of HIV and enhance patient outcomes.²³⁻²⁴

Role of Blood Transfusions in Supporting Lymphatic Function

Blood transfusions are a critical component in the management of HIV-positive individuals, particularly in addressing anemia and its related complications. Beyond their immediate impact on hematologic parameters, blood transfusions play a significant role in supporting lymphatic function and overall immune health. Anemia, a common complication in HIV-positive individuals, results in decreased hemoglobin levels and reduced oxygen-carrying capacity of the blood. This condition impairs oxygen delivery to various tissues, including lymphoid organs such as lymph nodes and the spleen. Blood transfusions help restore hemoglobin levels, thereby improving oxygenation of these vital tissues. Enhanced oxygen delivery supports cellular metabolism and function, contributing to the maintenance and repair of lymphoid tissue architecture. This improvement in tissue health is crucial for the effective functioning of lymph nodes and the spleen in immune responses.²⁵⁻²⁷ Chronic inflammation is a hallmark of HIV infection and contributes to the progressive damage of lymphoid tissues. Blood transfusions can help mitigate systemic inflammation by improving anemia and restoring normal hematologic function. By reducing the need for compensatory inflammatory responses that occur in the presence of anemia, transfusions indirectly decrease inflammatory stress on lymphoid tissues. This reduction in inflammation helps alleviate the burden on lymphatic tissues, supporting their ability to filter pathogens and mount effective immune responses.²⁸⁻²⁹

The restoration of hemoglobin levels through blood transfusions has direct benefits for immune cell function. Adequate oxygenation supports the metabolic needs of immune cells, including lymphocytes, which are crucial for immune responses. Transfusions help ensure that lymphocytes **Citation**: Obeagu EI, Obeagu GU. Supporting Lymphatic Function: Blood Transfusions in HIV and the Immune System. Elite Journal of Medical Sciences, 2024; 2(9):12-20

and other immune cells maintain their functionality, aiding in effective immune surveillance and pathogen clearance. By supporting the health of these cells, blood transfusions contribute to the overall integrity and efficiency of the lymphatic system.³⁰⁻³¹ Lymphoid tissues such as lymph nodes and the spleen play vital roles in immune responses by filtering lymph and blood, respectively, and presenting antigens to immune cells. Blood transfusions help support these functions by improving oxygenation and reducing tissue stress. Enhanced lymphoid tissue function translates to better immune surveillance and more effective immune responses against pathogens. This support is particularly important for HIV-positive individuals, who are at increased risk of opportunistic infections and require robust immune function to manage their condition effectively.³²⁻³³ The integration of blood transfusions into HIV care complements antiretroviral therapy (ART) by addressing anemia and supporting lymphatic function. While ART targets the viral load and helps restore immune function over time, transfusions provide immediate relief from anemia-related complications and support the health of lymphoid tissues. This combined approach enhances overall treatment efficacy and improves patient outcomes, contributing to a more comprehensive management strategy.³⁴⁻³⁵ The benefits of blood transfusions extend beyond the management of anemia, offering significant improvements in lymphatic function and immune health. By supporting tissue repair, reducing inflammation, and enhancing immune cell function, transfusions play a crucial role in improving the quality of life for HIV-positive individuals. The positive impact on lymphoid tissues and immune responses helps mitigate some of the challenges associated with HIV infection, leading to better disease management and overall well-being.³⁶⁻³⁷

Mechanisms of Blood Transfusions in Supporting Immune Function

Blood transfusions are not only pivotal in managing anemia in HIV-positive individuals but also play a significant role in supporting and enhancing immune function. This support is crucial for maintaining immune system integrity and improving patient outcomes. One of the primary mechanisms through which blood transfusions support immune function is by restoring hemoglobin levels to normal or near-normal ranges. Adequate hemoglobin is essential for effective oxygen transport throughout the body. By improving oxygen delivery to tissues, including lymphoid organs such as lymph nodes and the spleen, transfusions help maintain optimal conditions for immune cell function. Enhanced oxygenation supports the metabolic needs of immune cells, including lymphocytes, which are critical for immune responses.³⁸ Anemia and chronic inflammation often coexist in HIV-positive individuals, exacerbating each other and contributing to immune dysfunction. Blood transfusions can help alleviate anemia-related inflammation by restoring normal hemoglobin levels. This reduction in anemia-related inflammation reduces stress on lymphoid tissues and immune cells, promoting a more balanced immune response and mitigating the risk of further immune system compromise.³⁹

Lymphocytes, including T cells, B cells, and natural killer (NK) cells, are essential components of the adaptive and innate immune systems. Blood transfusions help improve the function of these cells by addressing anemia and ensuring that lymphocytes receive adequate oxygen and nutrients. Transfusions support lymphocyte proliferation, activation, and overall functionality, which

enhances the body's ability to mount effective immune responses against infections and other challenges. The health and functionality of lymphoid tissues, such as lymph nodes and the spleen, are crucial for effective immune responses. Blood transfusions contribute to the health of these tissues by improving oxygenation and reducing inflammation. By alleviating anemia, transfusions help maintain the structural and functional integrity of lymphoid tissues, enabling them to efficiently filter pathogens, present antigens to immune cells, and support the generation of immune responses.⁴⁰ Effective immune surveillance is vital for detecting and responding to infections and other threats. Blood transfusions support immune surveillance by improving the overall function of immune cells and lymphoid tissues. Enhanced oxygenation and reduced inflammation contribute to better immune cell function and more efficient pathogen detection. This improved surveillance capability helps the body respond more effectively to infections and other immune challenges. HIV infection leads to significant immune deficits, including the depletion of CD4+ T cells and disruption of lymphoid tissue architecture. Blood transfusions can help mitigate some of these deficits by improving overall immune function and supporting the health of remaining immune cells and lymphoid tissues. While transfusions do not directly address the underlying viral infection, they provide crucial support to the immune system, helping to counteract some of the negative effects of HIV on immune function.⁴¹

Implications for Comprehensive HIV Care

The integration of blood transfusions into comprehensive HIV care has profound implications for patient management and overall outcomes. As highlighted, blood transfusions support immune function and address anemia-related complications, which are common in HIV-positive individuals. Blood transfusions contribute to the restoration of hemoglobin levels, which improves oxygen delivery to tissues and supports immune cell function. This enhancement is crucial for managing the immune deficits associated with HIV. By improving the overall immune response, transfusions help patients better cope with opportunistic infections and other complications. This support complements antiretroviral therapy (ART), which targets the viral load and promotes immune recovery. The combined effect of transfusions and ART provides a more comprehensive approach to managing HIV, potentially leading to improved clinical outcomes and reduced morbidity.⁴² Anemia and related symptoms such as fatigue, weakness, and diminished physical capacity can significantly impact the quality of life in HIV-positive individuals. Blood transfusions alleviate these symptoms by restoring normal hemoglobin levels, thereby improving energy levels and overall physical functioning. Enhanced physical well-being can lead to better adherence to ART, increased participation in daily activities, and improved psychological health. By addressing both physical and emotional aspects of care, transfusions contribute to a more holistic approach to patient management. The health of lymphoid tissues, including lymph nodes and the spleen, is vital for effective immune surveillance and response. Blood transfusions help maintain the structural and functional integrity of these tissues by improving oxygenation and reducing inflammation. This support enhances the ability of lymphoid tissues to filter pathogens, present antigens, and mount immune responses. For HIV-positive patients, this means improved immune surveillance and a better ability to detect and respond to infections. Integrating transfusions into care plans helps sustain lymphoid tissue function and strengthens the overall immune system.⁴²

Chronic anemia and systemic inflammation are common complications in HIV-positive individuals. Blood transfusions address these issues by correcting anemia and reducing the inflammatory burden on the body. This mitigation of complications helps prevent or manage secondary health problems that can arise from anemia and inflammation. By integrating transfusions into comprehensive care, healthcare providers can address these complications proactively, reducing the risk of further health issues and improving overall patient stability.⁴³ The use of blood transfusions in HIV care underscores the importance of personalized treatment plans. Each patient's needs and responses to treatment can vary, making it essential to tailor interventions based on individual health status and treatment goals. Blood transfusions should be considered as part of a broader care strategy that includes ART, supportive therapies, and regular monitoring. Personalized care plans that incorporate transfusions as needed can optimize treatment outcomes and enhance patient satisfaction. Implementing blood transfusions in HIV care requires careful coordination among healthcare providers, including hematologists, infectious disease specialists, and primary care providers. A multidisciplinary approach ensures that transfusion therapy is integrated effectively into the overall treatment plan, addressing both hematologic and immunologic needs. Collaboration among specialists helps in managing potential risks associated with transfusions, such as transfusion reactions or infections, and ensures that patient care is comprehensive and well-coordinated.

Conclusion

Blood transfusions play a pivotal role in the comprehensive care of HIV-positive individuals by addressing key challenges such as anemia and supporting overall immune function. The mechanisms through which transfusions contribute to improved patient outcomes include the restoration of hemoglobin levels, reduction of systemic inflammation, and support for lymphoid tissue health. These effects collectively enhance immune surveillance, mitigate the complications associated with HIV, and improve quality of life for patients. Integrating blood transfusions into HIV care strategies complements antiretroviral therapy and other supportive treatments, creating a holistic approach to disease management. By improving physical health, alleviating anemia-related symptoms, and bolstering immune responses, transfusions help patients maintain better health and manage HIV more effectively. The benefits extend beyond immediate clinical outcomes, contributing to improved patient adherence to treatment and overall well-being.

References

- Ezeamama AE, Sikorskii A, Bajwa RK, Tuke R, Kyeyune RB, Fenton JI, Guwatudde D, Fawzi WW. Evolution of anemia types during antiretroviral therapy—implications for treatment outcomes and quality of life among HIV-infected adults. Nutrients. 2019;11(4):755.
- Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30

- Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206.
- 4. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review, 2024; 2(1): 37-50
- 5. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
- 6. Agreen FC, Obeagu EI. Anaemia among pregnant women: A review of African pregnant teenagers. Journal of Public Health and Nutrition. 2023;6(1):138.
- Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of protein C, protein S and fibrinogen of pregnant women with malaria in Owerri metropolis. Madonna University journal of Medicine and Health Sciences. 2022;2(2):1-9.
- 8. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www.journalijiar.com.;12(01).
- 9. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-43.
- 10. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32
- 11. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41
- 12. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV. 2024;2(1):16-30.
- 13. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
- 14. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
- 15. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
- 16. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review. 2024;2(1):24-36.
- 17. Montoro M, Cucala M, Lanas Á, Villanueva C, Hervás AJ, Alcedo J, Gisbert JP, Aisa ÁP, Bujanda L, Calvet X, Mearin F. Indications and hemoglobin thresholds for red blood cell transfusion and iron replacement in adults with gastrointestinal bleeding: An algorithm proposed by gastroenterologists and patient blood management experts. Frontiers in Medicine. 2022; 9:903739.
- 18. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.

- 19. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64
- 20. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. Elite Journal of Medicine, 2024; 2(1): 1-16
- 21. Kuldanek SA, Kelher M, Silliman CC. Risk factors, management and prevention of transfusion-related acute lung injury: a comprehensive update. Expert review of hematology. 2019;12(9):773-785.
- 22. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M, Anemia in HIV Working Group. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clinical infectious diseases. 2004;38(10):1454-1463.
- 23. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology. 2024;2(3):42-57.
- 24. Obeagu EI. The Impact of Howell-Jolly Bodies on Quality of Life in HIV Patients: A Review. Elite Journal of Public Health. 2024;2(5):32-42.
- 25. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine. 2024;2(1):10-22.
- 26. Peter T, Ellenberger D, Kim AA, Boeras D, Messele T, Roberts T, Stevens W, Jani I, Abimiku AL, Ford N, Katz Z. Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. The Lancet Infectious Diseases. 2017 ;17(1):e26-9.
- 27. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
- 28. Obeagu EI, Obeagu GU. Anemia in HIV: The Role of Erythropoietin in Disease Progression. Elite Journal of Haematology, 2024; 2 (4). 2024:51-67.
- 29. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents. MMWR. 2004;53(RR15):1-12.
- 30. Dikshit B, Wanchu A, Sachdeva RK, Sharma A, Das R. Profile of hematological abnormalities of Indian HIV infected individuals. BMC hematology. 2009; 9:1-6.
- 31. Volberding P. The impact of anemia on quality of life in human immunodeficiency virus infected patients. The Journal of infectious diseases. 2002;185(Supplement_2):S110-4.
- 32. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. Medicine. 2024;103(2):e36937.
- 33. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M, Anemia in HIV Working Group. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clinical infectious diseases. 2004;38(10):1454-1463.
- 34. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
- 35. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024;2(1):33-45.

- 36. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
- 37. Collier AC, Kalish LA, Busch MP, Gernsheimer T, Assmann SF, Lane TA, Asmuth DM, Lederman MM, Murphy EL, Kumar P, Kelley M. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. JAMA. 2001;285(12):1592-601.
- 38. Obeagu EI. Hematological Consequences of Erythropoietin in HIV: Clinical Implications. Elite Journal of Laboratory Medicine. 2024;2(6):1-9.
- 39. Muñoz M, Breymann C, García-Erce JA, Gómez-Ramírez S, Comin J, Bisbe E. Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox sanguinis. 2008;94(3):172-183.
- 40. Gould SA, Moss GS. Clinical development of human polymerized hemoglobin as a blood substitute. World journal of surgery. 1996 Nov;20(9):1200-1207.
- 41. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ, Viral Activation Transfusion Study Investigators*. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Annals of internal medicine. 2001;135(1):17-26.
- 42. Wiciński M, Liczner G, Cadelski K, Kołnierzak T, Nowaczewska M, Malinowski B. Anemia of chronic diseases: wider diagnostics—better treatment? Nutrients. 2020;12(6):1784.
- 43. Desai N, Schofield N, Richards T. Perioperative patient blood management to improve outcomes. Anesthesia & Analgesia. 2018;127(5):1211-1220.